AtriCure Announces Commencement of Public Offering of Common Stock

  AtriCure Announces Commencement of Public Offering of Common Stock  Business Wire  WEST CHESTER, Ohio -- February 12, 2014  AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders.  Piper Jaffray& Co. is acting as the sole book-running manager. Canaccord Genuity Inc., Leerink Partners LLC, Stifel and Barrington Research Associates are acting as co-managers for the offering.  This offering will be made pursuant to a prospectus supplement to AtriCure’s prospectus, dated January 15, 2014, filed as part of AtriCure’s effective $150million shelf registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.  Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Piper Jaffray& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.  About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide.The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.  Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as those relating to AtriCure’s expectations with respect to the proposed public offering, earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, AtriCure’s ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into AtriCure’s operations, AtriCure’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings, failure of an acquisition or acquired company to achieve its plans and objectives generally, risk that proposed or consummated acquisitions may disrupt operations or pose difficulties in employee retention or otherwise affect financial or operating results, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.  Contact:  AtriCure, Inc. Andy Wade, 513-755-4564 Vice President and Chief Financial Officer awade@atricure.com or Investor Relations Contact: Westwicke Partners Lynn Pieper, 415-202-5678 lynn.pieper@westwicke.com